$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016
[Published by Global Data]

Published by Global Data: 30 Aug 2016 | 27409 | In Stock
Related Topics: Clinical Trials , Multiple Myeloma , Myeloma

Introduction

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016" provides an overview of Relapsed Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
for Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

  • Table of Contents

    Table of Contents 2

    List of Tables 3

    List of Figures 4

    Report Guidance 5

    Clinical Trials by Region 6

    Clinical Trials and Average Enrollment by Country 7

    Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9

    Top Five Countries Contributing to Clinical Trials in Europe 10

    Top Countries Contributing to Clinical Trials in North America 11

    Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12

    Top Five Countries Contributing to Clinical Trials in Central and South America 13

    Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 14

    Clinical Trials by Phase in G7 Countries 15

    Clinical Trials in G7 Countries by Trial Status 16

    Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 17

    Clinical Trials by Phase in E7 Countries 18

    Clinical Trials in E7 Countries by Trial Status 19

    Clinical Trials by Phase 20

    In Progress Trials by Phase 21

    Clinical Trials by Trial Status 22

    Clinical Trials by End Point Status 23

    Subjects Recruited Over a Period of Time 24

    Clinical Trials by Sponsor Type 25

    Prominent Sponsors 26

    Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials 27

    Prominent Drugs 28

    Latest Clinical Trials News on Relapsed Multiple Myeloma 29

    Jul 28, 2016: AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma 29

    Clinical Trial Profile Snapshots 30

    Appendix 483

    Abbreviations 483

    Definitions 483

    Research Methodology 484

    Secondary Research 484

    About GlobalData 485

    Contact Us 485

    Disclaimer 485

    Source 486

List Of Tables
in Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Tables

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2016* 6

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10

Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016* 14

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016* 17

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2016* 20

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List Of Figures, Charts and Diagrams
in Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Figures

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10

Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016* 14

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15

Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16

Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016* 17

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18

Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24

Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27

Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 484

Additional Details

Publisher

Global Data

Publisher Information

Reference

27409 | GDHC3725CTIDB

Number of Pages

486

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Insight, 2017
DelveInsight’s, “Relapsed Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017”, report provid...
31 Jul 2017 by Delve Insight USD $1,250 More Info
Relapsed Chronic Lymphocytic Leukemia (CLL) - Market Insights, Epidemiology and Market Forecast – 2025
DelveInsight’s “Relapsed Chronic Lymphocytic Leukemia (CLL) - Market Insights, Epidemiology and Mar...
31 Jul 2017 by Delve Insight USD $5,750 More Info
Relapsed Chronic Lymphocytic Leukemia (CLL) - Epidemiology Insights to 2025
DelveInsight’s “Relapsed Chronic Lymphocytic Leukemia (CLL) -Epidemiology Forecast, 2025” provides a...
31 Jul 2017 by Delve Insight USD $2,950 More Info
Relapsed Chronic Lymphocytic Leukemia (CLL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s, Relapsed Chronic Lymphocytic Leukemia (CLL) - Global API Manufacturers, Marketed and...
01 Jul 2017 by Delve Insight USD $2,000 More Info
Relapsed Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017
DelveInsight’s, “ Relapsed Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017”, report provi...
30 May 2017 by Delve Insight USD $1,250 More Info
Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017
DelveInsight’s, “ Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL)-Pipeline Insights, 2017”, ...
30 May 2017 by Delve Insight USD $1,250 More Info
Relapsed Multiple Myeloma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Relapsed Multiple Myeloma-Global API Manufacturers, Marketed and Phase III D...
30 May 2017 by Delve Insight USD $2,000 More Info
Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016
Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H2, 2016SummaryGlobalData...
30 Aug 2016 by Global Data USD $2,500 More Info
Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016
Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016
Relapsed Acute Myeloid Leukemia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info

This report is published by Global Data

Download Free Report Summary PDF

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...